HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease.

AuthorsFleur Cohen-Aubart, Philippe Maksud, David Saadoun, Aurélie Drier, Frédéric Charlotte, Philippe Cluzel, Zahir Amoura, Julien Haroche
JournalBlood (Blood) Vol. 127 Issue 11 Pg. 1509-12 (Mar 17 2016) ISSN: 1528-0020 [Electronic] United States
PMID26847247 (Publication Type: Clinical Trial, Letter)
Chemical References
  • Interferon-alpha
  • Interleukin 1 Receptor Antagonist Protein
  • C-Reactive Protein
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Bone and Bones (diagnostic imaging, pathology)
  • C-Reactive Protein (analysis)
  • Central Nervous System (diagnostic imaging, pathology)
  • Disease Progression
  • Drug Resistance
  • Erdheim-Chester Disease (diagnostic imaging, drug therapy, pathology)
  • Fatigue (chemically induced)
  • Female
  • Heart (diagnostic imaging)
  • Humans
  • Interferon-alpha (therapeutic use)
  • Interleukin 1 Receptor Antagonist Protein (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Myocardium (pathology)
  • Organ Specificity
  • Pain (chemically induced)
  • Positron-Emission Tomography
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: